Bart Van Hooland, MBA
Bart Van Hooland is managing partner of Droia since 2012. Mr. Van Hooland oversees Droia’s operations, develops investment opportunities and manages portfolio investments. He also acted as interim CEO for 2 Droia portfolio companies. Mr. Van Hooland is director in Tusk Therapeutics, Bioncotech, Convert Pharmaceuticals and NormOxys, and board observer in Arcus Biosciences and PACT Pharma. Mr. Van Hooland graduated as an engineer from the University of Ghent and has an MBA from INSEAD. He worked as a strategy consultant at BCG in Paris and Brussels, and has since been owner, manager and director of several companies before co-founding Droia. Mr. Van Hooland is a member of the board of directors of Gimv, a Euronext listed private equity and venture capital investor. He is also on board of the Hermes Fund, which has succeeded IWT, the Flemish agency for innovation through science and technology, where he was a director. Both GIMV and IWT have been instrumental in the development of the Belgian biotech ecosystem.